SCHEMBL454801

SCHEMBL454801

NC(Cc1ccc(O)c(O)c1O)C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.58
HSD17B10 Q99714 4/20 0.58
ALDH1A1 P00352 4/20 0.58
LMNA P02545 4/20 0.58
MAPT P10636 4/20 0.58
PMP22 Q01453 4/20 0.58
KMT2A Q03164 4/20 0.58
USP2 O75604 3/20 0.58
TDP1 Q9NUW8 3/20 0.58
HIF1A Q16665 3/20 0.58
ALOX15 P16050 3/20 0.58
MEN1 O00255 3/20 0.58
CYP3A4 P08684 3/20 0.58
NPSR1 Q6W5P4 3/20 0.58
BLM P54132 3/20 0.58
RECQL P46063 2/20 0.58
CYP2C9 P11712 2/20 0.58
THPO P40225 2/20 0.58
PKM P14618 2/20 0.58
POLB P06746 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29216329 1.00 KDM4E (0.58) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL5287555 0.84 KDM4E (0.53) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL5284385 0.84 KDM4E (0.53) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL6046185 0.84 KDM4E (0.57) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL3467175 0.84 SLC7A5 (0.54) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL3467173 0.84 SLC7A5 (0.54) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL1700767 0.84 KDM4E (0.56) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL29540097 0.84 KDM4E (0.56) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL157790 0.84 KDM4E (0.56) KDM4EHSD17B10ALDH1A1LMNAMAPT
SCHEMBL27751535 0.83 KDM4E (0.49) KDM4EHSD17B10ALDH1A1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 211 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250270429-A1 PROTEIN-BASED ADHESIVE AND ITS MODIFICATION PURDUE RESEARCH FOUNDATION (US) 2025-08-28 US claimed
US-12331230-B2 Protein-based adhesive and its modification PURDUE RESEARCH FOUNDATION 2025-06-17 US claimed
CN-117925336-A Cleaning liquid after chemical mechanical polishing and preparation method and application thereof 浙江奥首材料科技有限公司 2024-04-26 CN claimed
WO-2023128791-A1 COMBINATION DRUG FOR EARLY DIAGNOSIS OF PARKINSON'S DISEASE ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ЦЕНТР РАННЕЙ ДИАГНОСТИКИ НЕЙРОДЕГЕНЕРАТИВНЫХ ЗАБОЛЕВАНИЙ" 2023-07-06 WO claimed
US-20210207013-A1 PROTEIN-BASED ADHESIVE AND ITS MODIFICATION PURDUE RESEARCH FOUNDATION (US) 2021-07-08 US claimed
WO-2020041557-A1 PROTEIN-BASED ADHESIVE AND ITS MODIFICATION PURDUE RESEARCH FOUNDATION (US) 2020-02-27 WO claimed
US-20190201349-A1 CAPSULES AND PARTICLES AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) 2019-07-04 US claimed
WO-2017072759-A1 CAPSULES AND PARTICLES AND USES THEREOF YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD (IL) 2017-05-04 WO claimed
EP-2306192-B1 Risk Markers For Cardiovascular Disease CLEVELAND CLINIC FOUNDATION (US) 2015-10-14 EP claimed
US-9005904-B2 Risk markers for cardiovascular disease THE CLEVELAND CLINIC FOUNDATION (US) 2015-04-14 US claimed
WO-2009114875-A2 OXIDIZED PARAOXONASE 1 AND PARAOXONASE 1/HDL PARTICLE NUMBER RATIO AS RISK MARKERS FOR CARDIOVASCULAR DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2009-09-17 WO claimed
CN-101384545-A Deuterated catecholamine derivatives and medicaments comprising said compounds BIRDS PHARMA GMBH BEROLINA INN (DE) 2009-03-11 CN claimed
US-7427690-B2 Multifunction “crown complexes” from amino acids and peptides for skin and hair restoration BIODERM RESEARCH (US) 2008-09-23 US claimed
EP-1697746-A4 RISK MARKERS FOR CARDIOVASCULAR DISEASE CLEVELAND CLINIC FOUNDATION (US) 2007-08-29 EP claimed
US-20070099886-A1 Multifunction \"Crown Complexes\" from Amino Acids and Peptides for Skin and Hair Restoration BIODERM RESEARCH (US) 2007-05-03 US claimed
EP-1697746-A2 RISK MARKERS FOR CARDIOVASCULAR DISEASE The Cleveland Clinic Foundation (US) 2006-09-06 EP claimed
US-20050239136-A1 Risk markers for cardiovacular disease THE CLEVELAND CLINIC FOUNDATION 2005-10-27 US claimed
WO-2005055810-A2 RISK MARKERS FOR CARDIOVASCULAR DISEASE THE CLEVELAND CLINIC FOUNDATION (US) 2005-06-23 WO claimed
US-5658885-A OLIGOPEPTIDES; ANTICOAGULANTS; ENZYME INHIBITORS; THROMBIN THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) 1997-08-19 US claimed
US-5047344-A Alteromonas Bacteria To Attract Oyster Larvae RESEARCH CORPORATION TECHNIQUES, INC. (US) 1991-09-10 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190201349-A1 CAPSULES AND PARTICLES AND USES THEREOF ALG1, LPO, FUT5 KDM4E 4642/4885HSD17B10 3106/4885ALDH1A1 1287/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.